TIANAFAC

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H9ClO2S
Molecular Weight	240.706
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(CC(O)=O)SC2=C1C=C(Cl)C=C2

InChI

InChIKey=QNJIHQOPIPJYLU-UHFFFAOYSA-N

InChI=1S/C11H9ClO2S/c1-6-8-4-7(12)2-3-9(8)15-10(6)5-11(13)14/h2-4H,5H2,1H3,(H,13,14)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4848056 | https://www.ncbi.nlm.nih.gov/pubmed/808225

Tianafac (also known as L8109) is a thienylacetic acid derivative patented by Labaz group as antipyretics and anti-inflammatory agent useful for the treatment of arthritis. In preclinical models, Tianafac inhibits prostaglandin formation by seminal vesicle microsomes and exerts antipyretic, analgetic, and moderate gastric ulcerogenic activity and had a wide safety margin between toxic and pharmacologically active doses.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostaglandin E synthase 9 Target ID: CHEMBL5658 Sources: https://www.ncbi.nlm.nih.gov/pubmed/808225	Inhibitor 8297		1.0 mM [IC50]

PubMed

Title	Date	PubMed
Correlation between anti-inflammatory properties and inhibition of prostaglandin biosynthesis in vitro.	1975 May 15	808225

Patents

Sample Use Guides

In Vivo Use Guide

rabbit: 4 mg/kg

Route of Administration: Oral

Name

Type

Language

TIANAFAC

Official Name

English

tianafac [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257